Clinical and epidemiological profile of genotype 3 HCV patients in the South of Brazil

Autores

  • Marisa Boff Costa 1.Pos-graduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil.
  • Larisse Longo 1.Pos-graduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil.
  • Deivid Santos 2. School of Medicine, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil.
  • Raquel Boff da Costa 1. Pos-graduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil.
  • Gustavo Hirata Dellavia 2.School of Medicine, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil.
  • Soraia Arruda 3.Department of Gastroenterology, Hospital de Clínicas de Porto Alegre. Porto Alegre, Brazil.
  • Matheus Truccolo Michalczuk 1. Pos-graduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil. 3. Department of Gastroenterology, Hospital de Clínicas de Porto Alegre. Porto Alegre, Brazil.
  • Mário Reis Álvares-da-Silva 1. Pos-graduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil. 2. School of Medicine, Universidade Federal do Rio Grande do Sul. Porto Alegre, Brazil. 3. Department of Gastroenterology, Hospital de Clínicas de Porto Alegre. Porto Alegre, Brazil.

Palavras-chave:

Hepatitis C, Liver Cirrhosis, Treatment, HCV-3, Genotypes

Resumo

Introduction and aim. Despite the emergence of new treatments for genotype 3 HCV (G3 HCV), there is still a lack of data about this particular subgroup in Brazil. We aimed to describe clinical and sociodemographic variables and treatment profile of G3 HCV Brazilian patients. Methods. This was a descriptive, retrospective study, performed in a specialized center for HCV treatment in Brazilian South Region. Medical charts of patients diagnosed with G3 HCV were reviewed to collect clinical, sociodemographic and treatment information. Results. 564 subjects were enrolled, with mean age of 59.3 years (SD=10.5). Cirrhosis was present in 54.4% of patients. Most common co-existent conditions were systemic arterial hypertension (36.6%) and diabetes mellitus (30.0%). Regarding treatment, 25.2% of patients were treatment-naïve and 74.8% were currently treating (11.6%) or had received a previous treatment (87.0%). The most frequent ongoing treatment was sofosbuvir+daclatasvir(± ribavirin) (87.8%). Of the 388 patients who had at least one previous treatment, 67.0% achieved sustained virologic response in the last treatment. Caucasian/white, non-obese, transplanted patients, those with longer time since diagnosis and with cirrhosis were more likely to receive treatment, according to multivariate analysis. Patients with hepatocellular carcinoma had 64.1% less chance to be on treatment during the study period than those without this condition; patients with chronic kidney disease presents were 2.91-fold more likely to have a treatment interruption than those without. Conclusion. This study describes a large sample of Brazilian patients with G3 HCV. Treatment patterns were mainly influenced by presence of HCV complications and comorbidities.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2020-07-15

Como Citar

1.
Costa MB, Longo L, Santos D, Costa RB da, Dellavia GH, Arruda S, Michalczuk MT, Álvares-da-Silva MR. Clinical and epidemiological profile of genotype 3 HCV patients in the South of Brazil. Clin Biomed Res [Internet]. 15º de julho de 2020 [citado 28º de junho de 2022];40(1). Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/100617

Edição

Seção

Artigos Originais